Inmed pharmaceuticals announces publication of peer-reviewed article on the use of cbn as a potential treatment for glaucoma

Vancouver, british columbia, dec. 20, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific article entitled “cannabinol modulates neuroprotection and intraocular pressure: a potential multi-target therapeutic intervention for glaucoma”, has been published in biochimica et biophysical acta (bba - molecular basis of disease), a leading international journal focused on biochemistry and molecular genetics of disease processes and models of human disease in the area of aging, cancer, metabolic-, neurological-, and immunological-based diseases.
INM Ratings Summary
INM Quant Ranking